Abstract P2-08-12: Initial real world treatment patterns and outcomes of Abemaciclib for the treatment of HR+,HER2- metastatic breast cancer

Abstract Background: Abemaciclib is a selective continually dosed cyclin-dependent kinase 4 and 6 (CDK 4 2 years20.8≥ 2 years79.2Menopausal statusb:Post-menopausal93.2Pre-menopausal6.8Modified Charlson comorbidity index (CCI) statusc:0/Unknown72.0116.928.53+2.5Number of sites of metastases, median IQRd2.0 1.0:3.0Presence of lung metastases34.7Presence of liver metastases22.9Presence of brain metastases7.6Follow-up time (months), median IQR6.4 4.1:9.5a: Patients not metastatic at initial diagnosis (n=77)b: Derived using age and evidence of gonadotropin-releasing hormone agonistc: Excludes cancer diagnosisd: Interquartile Range (IQR) Citation Format: Gebra Cuyun Carter, Kristin M Sheffield, Anala Gossai, Yu-Jing Huang, Yajun Emily Zhu, Lee Bowman, Emily Nash Smith, Raina Mathur, Aaron B Cohen, Shrujal Baxi, Sarah Rybowski, Amy Lee Chong, Andrew D Seidman. Initial real world treatment patterns and outcomes of Abemaciclib for the treatment of HR+,HER2- metastatic breast cancer abstract. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-08-12.